Mr Michael Vincent Roots, LCSW, CAC | |
Installation Management Agency-e, Attn:sfim-eu-hr (saic-asacs) Unit 29353 Box 200, Apo, AE 09014 | |
(004) 962-21163912 | |
Not Available |
Full Name | Mr Michael Vincent Roots |
---|---|
Gender | Male |
Speciality | Social Worker - Clinical |
Location | Installation Management Agency-e, Apo, Armed Forces Europe |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1972521755 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YA0400X | Counselor - Addiction (substance Use Disorder) | 4089 (Pennsylvania) | Primary |
1041C0700X | Social Worker - Clinical | 011768L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Michael Vincent Roots, LCSW, CAC Psc3, Box 1624, Apo, AE 09021 Ph: (004) 963-71915800 | Mr Michael Vincent Roots, LCSW, CAC Installation Management Agency-e, Attn:sfim-eu-hr (saic-asacs) Unit 29353 Box 200, Apo, AE 09014 Ph: (004) 962-21163912 |
News Archive
A new study that surveyed physicians and nurses in hospitals within cancer centers in Germany suggests that many patients there do not experience a dignified death.
Research published in The New England Journal of Medicine shows that disease and mortality due to smoking have continually increased over the past 50 years in the USA.
A new qualitative study by researchers at Columbia University Mailman School of Public Health found that the majority of women living with HIV would endorse a monthly long acting injectable (LAI) antiretroviral therapy over current daily pills.
VIVUS, Inc. today announced the issuance of three additional patents by the U.S. Patent and Trademark Office (USPTO) covering Qnexa, an investigational new drug candidate for the treatment of obesity. The three new patents are the second, third, and fourth patents to be granted in a series of patent applications VIVUS has filed that are directed to the Qnexa product and methods of using Qnexa in various therapeutic applications.
DestinationRx celebrated the company's 10th anniversary with an announcement at the Health 2.0 Conference today. Even as sweeping healthcare reform is debated in Congress, this observance marks an important milestone for the health plan and drug comparison industry leader.
› Verified 5 days ago